Skip to content


• Solid cash position of €16.3 million at December 31, 2017
• TANGO timing update: results postponed, full 12 month results expected in Q4
2018 per protocol
• Progression in the clinical developments of CER-209 in NASH and NAFLD
• Extension of the CERENIS HDL platform for immuno-oncology and chemotherapy

Toulouse, FRANCE, Lakeland, UNITED-STATES, February 1st, 2018, 7.00 pm CET – CERENIS Therapeutics (FR0012616852 – CEREN – PEA PME eligible), an international biopharmaceutical
company dedicated to the discovery and development of HDL-based innovative therapies for treating cardiovascular and metabolic diseases, as well as new HDL-based vectors for targeted drug delivery in the field of oncology, today announces its full-year 2017 financial results, as approved by the Board of
Directors on February 1st, 2018. Audit procedures on statutory and consolidated accounts have been performed by the auditors and certification report is currently being issued.

Please find attached the complete press release.

Source: Cerenis Therapeutics